ReviewPharmacology & therapeutics2007
Type 1 angiotensin receptor pharmacology: signaling beyond G proteins.
Review in Pharmacology & therapeutics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 93 citations in OpenAlex.
- Association of Polymorphisms in Endothelial Nitric Oxide Synthesis and Renin-Angiotensin-Aldosterone System with Developing of Coronary Artery Disease in Bulgarian Patients.Genetic testing and molecular biomarkers · 2016Trial
- Increased Salt-Sensitive Blood Pressure in Women vs Men: Is Relative Hyperaldosteronism the Mechanism?The Journal of clinical endocrinology and metabolism · 2025Article
- Mechanisms of angiotensin II to induce depression in diabetes.Diabetology international · 2025Review
- Structural basis for the ligand recognition and G protein subtype selectivity of kisspeptin receptor.Science advances · 2024Article
- Review
- Phospholipase C-β3 is dispensable for vascular constriction but indispensable for vascular hyperplasia.Experimental & molecular medicine · 2024Article
- Differential expression of the angiotensin receptors (AT1, AT2, and AT4) in the placental bed of HIV-infected preeclamptic women of African ancestry.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Article
- The ATMolecules (Basel, Switzerland) · 2023Review
- Neuropathology of incidental Lewy body & prodromal Parkinson's disease.Molecular neurodegeneration · 2023Review
- AT1 receptor downregulation: A mechanism for improving glucose homeostasis.World journal of diabetes · 2023Review
- Angiotensin II Type I Receptor (AT1R): The Gate towards COVID-19-Associated Diseases.Molecules (Basel, Switzerland) · 2022Review
- Protective Effect of Renin-Angiotensin System Inhibitors on Parkinson's Disease: A Nationwide Cohort Study.Frontiers in pharmacology · 2022Article
- The Roles of GRKs in Hemostasis and Thrombosis.International journal of molecular sciences · 2020Review
- Paracrine and Intracrine Angiotensin 1-7/Mas Receptor Axis in the Substantia Nigra of Rodents, Monkeys, and Humans.Molecular neurobiology · 2018Article
- The renin-angiotensin system: a possible new target for depression.BMC medicine · 2017Review
- Brain Renin-Angiotensin System and Microglial Polarization: Implications for Aging and Neurodegeneration.Frontiers in aging neuroscience · 2017Review
- A single mutation in helix 8 enhances the angiotensin II type 1a receptor transport and signaling.Cellular signalling · 2015Article
- International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].Pharmacological reviews · 2015Review
- A state of reversible compensated ventricular dysfunction precedes pathological remodelling in response to cardiomyocyte-specific activity of angiotensin II type-1 receptor in mice.Disease models & mechanisms · 2015Article
- G protein-coupled receptors in cardiac biology: old and new receptors.Biophysical reviews · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drugs that inhibit the production of angiotensin II (AngII) or its access to the type 1 angiotensin receptor (AT(1)R) are prescribed to alleviate high blood pressure and its cardiovascular complications. Accordingly, much research has focused on the molecular pharmacology of AT(1)R activation and signaling. An emerging theme is that the AT(1)R generates G protein dependent as well as independent signals and that these transduction systems separately contribute to AT(1)R biology in health and disease. Regulatory molecules termed arrestins are central to this process as is the capacity of AT(1)R to crosstalk with other receptor systems, such as the widely studied transactivation of growth factor receptors. AT(1)R function can also be modulated by polymorphisms in the AGTR gene, which may significantly alter receptor expression and function; a capacity of the receptor to dimerize/oligomerize with altered pharmacology; and by the cellular environment in which the receptor resides. Together, these aspects of the AT(1)R "flavour" the response to angiotensin; they may also contribute to disease, determine the efficacy of current drugs and offer a unique opportunity to develop new therapeutics that antagonize only selective facets of AT(1)R function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.